In Cambridge, we work with organisations of all sizes, from global pharma and biotech leaders to emerging medtech and data-driven companies, to transform cutting-edge research into new diagnostics, therapies, and technologies.
Key industry partnerships
Cambridge-GSK Translational Immunology Collaboration (CG-TIC)
CG-TIC combines University and GSK expertise in the science of the immune system, AI and clinical development with access to patients and their data provided by Cambridge University Hospitals. The ambition of this 5-year £53m partnership is to treat immune-related diseases more precisely with existing therapies and to rapidly develop new ones.
Biomarkers for RAtional Investigation for Neurological decision Support in TBI: BRaINS-TBI
Led by Dr Virginia Newcombe and collaborating with groups including Headway and UKABIF, BRAINS-TBI is a cohort study of 2048 patients with embedded RCT of ~800 patients who present to 10 UK Emergency Departments after sustaining a mild traumatic brain injury.
With funding of over £3m from NIHR, the study will utilise the UKRI Platform for TBI research (TBI-REPORTER). It aims to answer two key questions:
- Can blood biomarkers reduce the number of CT scans performed in the ED for mild TBI?
- Can Biomarkers identify patients at higher risk of long-term problems following mild TBI?
Case studies
T-Therapeutics: revolutionising the clinical landscape for cancer patientsBuilt on the foundations of research from Professor Allan Bradley in the University’s Department of Medicine, T-Therapeutics’ OpTiMus® platform sidesteps shortfalls in immuno-oncology by creating a near-unlimited database of optimal T cell receptors (TCRs). |
I am brain aware: brain injury app to improve patient careSupported by NIHR, Dr Virginia Newcomb and her research team are developing an evidence guided, app-based support and intervention programme called PCS-AWARE, to help patients self-manage post-concussion symptoms (PCS). |
|
|
|
|
|
|
|
|
|
